

CURRICULUM VITAE

Nazionalità:	Italiana
Residenza:	Novara, Italia
Formazione:	1997-2001: Dottorato di Ricerca in Oncologia Umana, XIII ciclo, Dipartimento di Scienze Biomediche e Oncologia, Università di Torino. 1992-1997: Specializzazione in Patologia Clinica - Università di Torino. Valutazione 70/70 lode. 1992: 26 Marzo: Laurea in Medicina e Chirurgia - Università di Torino, Valutazione 110/110 e Dignità di stampa. Aprile: Abilitazione alla Professione di Medico Chirurgo.
Indirizzo di lavoro:	Università del Piemonte Orientale, Dipartimento di Scienze della Salute, Via P. Solaroli 17, 28100 Novara - Italia
Telefono di lavoro:	+39 0321 660674 (Ufficio), +39 0321 660679/660664 (Laboratorio)
E-mail:	antonia.follenzi@med.uniupo.it or afollenzi@gmail.com

PREMI E RICONOSCIMENTI

2016:	Premio per la Ricerca svolta presso l'Università del Piemonte Orientale.
2010:	CSL-Behring Prof. Heimburger Award startup per ricercatori che cominciano progetti su malattie della coagulazione.
2008:	Premiata dall'European Society of Gene and Cell Therapy con il premio "Young Investigator Award", Bruges, Belgio.
2005:	Vincitrice del "Liver Scholar Award" dell'American Liver Foundation (ALF) e dell'American Association for the Study of Liver Diseases (AASLD) per giovani ricercatori coinvolti nello studio delle malattie del fegato. "Career Development Award" della National Hemophilia Foundation (rinuncia in favore del premio ricevuto dall'ALF perche incompatibili contemporaneamente).
2000:	American Society for Gene Therapy Travel Grant Award. Premiata al III° congresso dell' American Society of Gene Therapy (Denver USA, Giugno 2000) per "Outstanding Research Award for Students and Fellows".
2000-2001:	Titolare di una Borsa di Studio dell'Istituto Superiore della Sanità per lo studio dell'HIV.
1996:	Titolare di una borsa di studio annuale per l'estero della Federazione Italiana per la ricerca sul Cancro "FIRC", presso il Weizmann Institute of Science, Rehovot (Israel), nel Dipartimento di Biological Regulation, responsabile il Professor Y. Yarden.
1989-1990:	Titolare di una borsa biennale del Comitato Regionale Piemontese "Gigi Ghirotti", presso il Dipartimento di Scienze Biomediche e Oncologia Umana dell'Università di Torino, responsabile il Prof. P.M. Comoglio.

CARRIERA ACCADEMICA

Dal 10/2017:	Professore Ordinario Istologia (BIO/17) presso la Scuola di Medicina e Dipartimento di Scienze della Salute dell'Università del Piemonte Orientale, Novara.
2013- 2017:	Professore Associato Istologia (BIO/17) presso la Scuola di Medicina e Dipartimento di Scienze della Salute dell'Università del Piemonte Orientale, Novara.
2006-2013:	Ricercatore di Istologia (BIO/17) presso la Scuola di Medicina e Dipartimento di Scienze

della Salute dell'Università del Piemonte Orientale, Novara.

- 2006-2019: Visiting Assistant Professor of Pathology, Albert Einstein College of Medicine, Bronx, NY.
- 2003-2006: Research Associate e Instructor presso il Marion Bessin Liver Research Center, Department of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, NY (Prof. Sanjeev Gupta).
- 2001-2003: Assegnista di Ricerca presso il Dipartimento di Scienze Biomediche e Oncologia Umana (successivamente di Scienze Oncologiche) presso IRCC di Candiolo (TO) con il Prof. Luigi Naldini.
- 1998: Stage "Lentiviral Vectors technology at Cell Genesys" (Foster City, CA) sotto la supervisione del Prof. L. Naldini, (Settembre a Dicembre).
- 1997-2000: Dottoranda in Oncologia Umana (Università di Torino) presso il Dipartimento di Scienze Biomediche e Oncologia Umana, nella sezione di Oncologia Molecolare del Prof. P.M. Comoglio durante il primo anno di dottorato, e nel laboratorio di Terapia Genica del Prof. L.Naldini durante il 2° e 3°, presso l'IRCC di Candiolo (TO).
- 1996-1997: Borsista AIRC-FIRC per l'estero (Israele) presso il Dipartimento di Molecular Cell Biology del Weizmann Institute of Science, Rehovot (Israele) nel laboratorio del Prof. Yosef Yarden.

CAMPI DI INDAGINE DELLA RICERCA

- Trasferimento genico mediante l'utilizzo di vettori lenti virali;
- Targeting trascrizionale e post-trascrizionale nell'espressione genica mediante vettori lentivirali;
- Terapia genica e cellulare utilizzando cellule parenchimali (epatociti) e non parenchimali del fegato (cellule endoteliali dei sinusoidi epatici e cellule del Kupffer);
- Emofilia A e B;
- Terapia genica contro il cancro utilizzando vettori lentivirali e nanoparticelle magnetiche

TEMI CORRENTI DI RICERCA

Terapia cellulare e genica dell'Emofilia A

Per curare l'emofilia A, malattia in cui manca il fattore VIII della coagulazione, un nuovo approccio è rappresentato dalla ricerca sulle cellule capaci di produrre FVIII. Abbiamo recentemente dimostrato che le cellule endoteliali dei sinusoidi epatici (LSEC) producono e secernono FVIII, anche se non sono le uniche. Abbiamo dimostrato che animali deficitari di FVIII possono essere curati somministrando midollo osseo sano, il che indica che le cellule del midollo osseo, di origine emopoietica, mesenchimale o anche endoteliale, possono produrre e secernere FVIII. Sulla base di questi risultati ottenuti nei topi proponiamo che LSEC, cellule da cordone ombelicale o da midollo osseo di origine umana, possano essere sorgenti adatte a produrre FVIII in una terapia cellulare sostitutiva per il trattamento dell'emofilia A. L'attività di ricerca finora svolta riguarda principalmente la terapia cellulare e genica dell'emofilia A e il trapianto di cellule epatiche ed ematopoietiche in diversi modelli di malattia, con particolare riguardo alle implicazioni della biologia cellulare e molecolare dei processi di attecchimento e proliferazione di cellule endoteliali, macrofagi ed epatociti.

ATTUALI COLLABORAZIONI SCIENTIFICHE

Con Sanjeev Gupta, MD; Laura Santambrogio, MD, PhD at Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, Yelena Ginzburg, MD (Mount Sinai School of Medicine, New York,

USA); Ombretta Salvucci, PhD (NCI/NIH, Bethesda, MD); Angel Raya, MD, PhD (CRMB, Barcellona, Spagna); Irma Dianzani e Rita Carini (Università del Piemonte Orientale, Dipartimento di Scienze della Salute, Novara, Italia); Prof. Enrica Vernè, PhD (Politecnico di Torino, Italia). Prof. Silvia Giordano (IRCCS Candiolo - TO, Italia); Prof. Amedeo Columbano (Università di Cagliari, Dip. di Scienze Biomediche, Cagliari, Italia); Prof. Luigi Naldini, (Vita e Salute - San Raffaele, TIGET, Milano, Italia).

GRANTS

- Telethon 2019, grant number GGP19201 (2019-2021)
“From coagulation to angiogenesis: new roles for FVIII in endothelial functionality”
- Horizon 2020, grant number 874700 (2020-2024)
Research and Innovation Action (RIA) H2020-SC1-BHC-07-2019 Vanguard: New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes
- Horizon 2020 11/2015 -10/2018, HemAcure – "Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe Hemophilia A".
<http://www.hemacure.eu/>
- ERC 05/2011- 04/2017 Start-up Project Number: 261178, CGT hemophilia A - “Cell and gene therapy based strategies to correct the bleeding phenotype in Hemophilia A”.
- AIRC 1/2013 - 06/2016 Grant n. 13166: “Development of engineered magnetic nanoparticles for cancer therapy”.
- Bando Ateneo Compagnia S.Paolo 04/2013 - 04/2016, "Development of Engineered Magnetic Nanoparticles for Targeted Therapies (LV-MNPs)".
- E-RARE Joint transnational call 2011 project: HEMO-iPS among Italy (Dr. A. Follenzi and PC Schinco), France (Dr. A. Weber and A. Dubart) and Spain (Dr. J.Barquinero, A. Raya and F. Vidal). 1-2-2012 to 31-12-2014.
- Telethon Grant (2010-2013) n.GGP09280: “Therapeutic roles of healthy donor human liver sinusoidal endothelial cells (LSEC), bone marrow or cord blood-derived cells in Hemophilia A”.
- 5 Grants dalla Regione Piemonte “Ricerca Sanitaria Finalizzata” dal 2006 al 2009 (12.000 Euro per Grant per un totale di 60.000 Euro).
2006: “Trasferimento genico mediante l'uso di vettori lentivirali in cellule endoteliali del fegato per la terapia dell'emofilia”.
2007: “Terapia cellulare e genica del fegato mediante trapianto di epatociti e cellule endoteliali dei sinusoidi epatici”
2008: “Ripopolamento del pool macrofagico residente nel fegato mediante trapianto di cellule di Kuppfer e/o di macrofagi differenziati dal midollo”
2008 bis: “Terapia genica della beta-talassemia mediante iperespressione della transferrina tramite uso di vettori lentivirali”
2009: “Utilizzo di progenitori ematopoietici derivati da midollo o da sangue di cordone per la terapia cellulare dell’Emofilia A”
- PRIN 2008 from Ministero dell’Istruzione, dell’Università e della Ricerca - Italy. Title: “Development of cell and gene therapy approach for Hemophilia A” (2010-2011).

INCARICHI ACCADEMICI

Dal 2013: Membro della Commissione Ricerca del Dipartimento di Scienze della Salute, Università del Piemonte Orientale, sede di Novara.

- 2014-2016: Incaricata del Dipartimento di Scienze della Salute nella Commissione di Ateneo per l'Internazionalizzazione, Università del Piemonte Orientale, sede di Novara.
- 2012-2016: Componente della Giunta del Dipartimento di Scienze della Salute, Università del Piemonte Orientale, sede di Novara.
- 2007-2019: Componente del corpo docenti del Dottorato di Ricerca in Biotecnologie per l'Uomo.
- Dal 2018: Presidente del Corso di Studio di Infermieristica dell'Università del Piemonte Orientale
- Dal 2019: Coordinatore del corso di Dottorato "Food, Health and Longevity" della Scuola di Medicina dell'Università del Piemonte Orientale

INCARICHI SCIENTIFICI

- 2010 - ad oggi: Revisore di progetti di Ricerca per il MIUR, Genethon (Francia) e il Fonds Wetenschappelijk Onderzoek (FWO) in Belgio, CAXIA in Spagna
- 2008 - ad oggi: Revisore per riviste internazionali indicizzate: Human Gene Therapy, Journal of Gene Medicine, Stem Cells, Journal of Clinical Investigation, Experimental Cell Research, Liver International, Blood, PLOS ONE, Molecular Therapy, Haematologica, Journal of Thrombosis and Haemostasis.

BREVETTI

1. Endothelial-Specific Promoter Sequences and Uses Thereof. WO2019021238, 2019-01-31
2. Method for Inducing and Differentiating Pluripotent Stem Cells and Uses Thereof. WO2018025130, 2018-02-08
3. Promoter for Cell-Specific Gene Expression and Uses Thereof. WO2017212460, 2017-12-14
4. Methods of Treatment of Hemophilia. US20130071361, 25-08-2011.

ASSOCIAZIONI SCIENTIFICHE

Iscritta a diverse società scientifiche tra le quali l'American Society of Gene and Cell Therapy (dal 2000), l'American Association for the Study of Liver Diseases (2004-2009), l'European Association for the Study of the Liver (2015-2019), l'European Society of Gene and Cell Therapy (dal 2008) e l'International Society of Thrombosis and Hemostasis (dal 2011).

PUBBLICAZIONI

(h-index:41 Scopus Agosto 2020)

1. Famà R, Borroni E, Merlin S, Airoidi C, Pignani S, Cucci A, Corà D, Brusca V, Scardellato S, Faletti S, Pelicci G, Pinotti M, Walker GE, **Follenzi A Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy** (2020). Haematologica. 2020 May 28: haematol.2019.239202. doi: 10.3324/haematol.2019.239202.
2. Famà R, Borroni E, Zanolini D, Merlin S, Brusca V, Walker GE, Olgasi C, Babu D, Agnelli Giacchello J, Valeri F, Giordano M, Borchiellini A, **Follenzi A. Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A** (2020). J Thromb Haemost. 2020 May;18(5):1050-1064. doi.org/10.1111/jth.14779
3. Merlin S, Famà R, Borroni E, Zanolini D, Brusca V, Zucchelli S, Follenzi A. **FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.** Blood Adv. 2019 Mar 12;3(5):825-838. doi: 10.1182/bloodadvances.2018027979
4. Olgasi C, Talmon M, Merlin S, Cucci A, Richaud-Patin Y, Rinaldo G, Colangelo D, Di Scipio F,

- Berta GN, Borsotti C, Valeri F, Faraldi F, Prat M, Messina M, Schinco P, Lombardo A, Raya A, Follenzi A. **Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A**. *Stem Cell Reports*. 2018 Dec 11;11(6):1391-1406. doi: 10.1016/j.stemcr.2018.10.012. Epub 2018 Nov 8. PMID: 30416049
5. Sharma Y, Liu J, Kristian KE, Follenzi A, Gupta S. **In Atp7b-/- Mice Modeling Wilson's Disease Liver Repopulation with Bone Marrow derived Myofibroblasts or Inflammatory Cells and not Hepatocytes is Deleterious**. *Gene Expr*. 2018 Dec 14;19(1):15-24. doi: 10.3727/105221618X15320123457380. Epub 2018 Jul 20.
 6. Merlin S, Cannizzo ES, Borroni E, Brusca V, Schinco P, Tulalamba W, Chuah MK, Arruda VR, VandenDriessche T, Prat M, Valente G, **Follenzi A**. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. *Mol Ther*. 2017 Aug 2;25(8):1815-1830. doi: 10.1016/j.ymthe.2017.04.029.
 7. Aspesi A, Monteleone V, Betti M, Actis C, Morleo G, Sculco M, Guarrera S, Wlodarski MW, Ramenghi U, Santoro C, Ellis SR, Loreni F, Follenzi A, Dianzani I. **Lymphoblastoid cell lines from Diamond Blackfan anaemia patients exhibit a full ribosomal stress phenotype that is rescued by gene therapy**. *Sci Rep*. 2017 Sep 20;7(1):12010. doi: 10.1038/s41598-017-12307-5
 8. Benten D, Kluwe J, Wirth JW, Thiele ND, **Follenzi A**, Bhargava KK, Palestro CJ, Koepke M, Tjandra R, Volz T, Lutgehetmann M, Gupta S. **A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells**. *Lab Invest*. 2018 Apr;98(4):525-536. doi: 10.1038/s41374-017-0010-7. Epub 2018 Jan 19.
 9. Martorell L, Luce E, Vazquez JL, Richaud-Patin Y, Jimenez-Delgado S, Corrales I, Borrás N, Casacuberta-Serra S, Weber A, Parra R, Altisent C, Follenzi A, Dubart-Kupperschmitt A, Raya A, Vidal F, Barquinero J. **Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA**. *J Thromb Haemost*. 2017 Nov;15(11):2188-2197. doi: 10.1111/jth.13808. Epub 2017 Sep 25.
 10. Ricci M, Miola M, Multari C, Borroni E, Canuto RA, Congiusta N, Vernè E, **Follenzi A**, Muzio G. **PPARs are mediators of anti-cancer properties of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with conjugated linoleic acid**. *Chem Biol Interact*. 2018 Aug 25;292:9-14. doi: 10.1016/j.cbi.2018.07.003. Epub 2018 Jul 3.
 11. Aspesi A, Betti M, Sculco M, Actis C, Olgasi C, Wlodarski MW, Vlachos A, Lipton JM, Ramenghi U, Santoro C, **Follenzi A**, Ellis SR, Dianzani I. **A functional assay for the clinical annotation of genetic variants of uncertain significance in Diamond-Blackfan anemia**. *Hum Mutat*. 2018 Aug;39(8):1102-1111. doi: 10.1002/humu.23551. Epub 2018 May 28.
 12. Walker GE, **Follenzi A**, Brusca V, Manfredi M, Bellone S, Marengo E, Maiuri L, Prodam F, Bona G. **Fetuin B links vitamin D deficiency and pediatric obesity: Direct negative regulation by vitamin D**. *J Steroid Biochem Mol Biol*. 2018 Sep;182:37-49. doi: 10.1016/j.jsbmb.2018.04.009. Epub 2018 Apr 21.
 13. Imarisio C, Alchera E, Bangalore Revanna C, Valente G, Follenzi A, Trisolini E, Boldorini R, Carini R. **Oxidative and ER stress-dependent ASK1 activation in steatotic hepatocytes and Kupffer cells sensitizes mice fatty liver to ischemia/reperfusion injury**. *Free Radic Biol Med*. 2017 Nov;112:141-148. doi: 10.1016/j.freeradbiomed.2017.07.020. Epub 2017 Jul 21.
 14. Borroni E, Miola M, Ferraris S, Ricci G, Žužek Rožman K, Kostevšek N, Catizone A, Rimondini L, Prat M, Vernè E, Follenzi A. **Tumor targeting by lentiviral vectors combined with magnetic nanoparticles in mice**. *Acta Biomater*. 2017 Sep 1;59:303-316. doi: 10.1016/j.actbio.2017.07.007. Epub 2017 Jul 5.

15. Merlin S, Cannizzo ES, Borroni E, Brusca V, Schinco P, Tulalamba W, Chuah MK, Arruda VR, VandenDriessche T, Prat M, Valente G, **Follenzi A. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.** *Mol Ther.* 2017 May 26. pii: S1525-0016(17)30215-0. doi: 10.1016/j.ymthe.2017.04.029. [Epub ahead of print]. PMID: 28552407. With a commentary by Jobson J and Brown BD. Micromanaging Tolerance in Hemophilia A Gene Therapy <http://dx.doi.org/10.1016/j.ymthe.2017.06.001>.
16. Muzio G, Miola M, Ferraris S, Maggiora M, Bertone E, Puccinelli MP, Ricci M, Borroni E, Canuto RA, Verné E, **Follenzi A. Innovative superparamagnetic iron-oxide nanoparticles coated with silica and conjugated with linoleic acid: Effect on tumor cell growth and viability.** *Mater Sci Eng C Mater Biol Appl.* 2017 Jul 1;76:439-447. doi: 10.1016/j.msec.2017.03.063. Epub 2017 Mar 10.
17. Li H, Choesang T, Bao W, Chen H, Feola M, Garcia dos Santos D, Li J, Sun S, **Follenzi A, Petra Pham P, Liu J, Zhang J, Ponka P, An X, Narla M, Fleming R, Rivella S, Li G, and Ginzburg Y Decreasing TfR1 expression reverses anemia and hepcidin suppression in beta-5thalassemic mice.** *Blood.* 2017 Feb 1. pii: blood-2016-09-742387. doi: 10.1182/blood-2016-09-742387. [Epub ahead of print]. PMID: 28151426
18. Angioni MM, Bellofatto K, Merlin S, Menegon S, Perra A, Petrelli A, Sulas P, Giordano S, Columbano A and **Follenzi A. A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis.** *Oncotarget* 2017 Feb 1. doi: 10.18632/oncotarget.14984. [Epub ahead of print]. PMID: 28157710
19. Deola S, Cugno C, Comoli P, Guido I, Rubert L, Zecca M, Zanolini D, **Follenzi A, Langes M, Negri G, Tauber M, Pusceddu I, Cavattoni I, Svaldi M, Grigoleit GU, Baumeister E, Wang E, Rutella S, Marincola FM. Evidence for CD19B-CD8T cell interactions in blood and tissues from patients with GvHD.** *Bone Marrow Transplant.* 2016 Nov 7. doi: 10.1038/bmt.2016.294. [Epub ahead of print]. PMID: 27819685
20. Ali R, Babad J, **Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.** *Immunology.* 2016 Aug;148(4):339-51. doi: 10.1111/imm.12613.
21. Merlin S, Bhargava KK, Ranaldo G, Zanolini D, Palestro CJ, Santambrogio L, Prat M, **Follenzi A, Gupta S. Kupffer Cell Transplantation in Mice for Elucidating Monocyte/Macrophage Biology and for Potential in Cell or Gene Therapy.** *Am J Pathol.* 2016 Mar;186(3):539-51. doi: 10.1016/j.ajpath.2015.11.002.
22. Clement CC, Becerra A, Yin L, Zolla V, Huang L, Merlin S, **Follenzi A, Shaffer SA, Stern LJ, Santambrogio L. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.** *J Biol Chem.* 2016 Mar 11;291(11):5576-95. doi: 10.1074/jbc.M115.655738.
23. Chen H, Choesang T, Li H, Sun S, Pham P, Bao W, Feola M, Westerman M, Li G, **Follenzi A, Blanc L, Rivella S, Fleming RE, Ginzburg YZ. Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation.** *Haematologica.* 2016 Mar;101(3):297-308. doi: 10.3324/haematol.2015.127902.
24. Rolla S, Alchera E, Imarisio C, Bardina V, Valente G, Cappello P, Mombello C, Follenzi A, Novelli F, Carini R. **The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice.** *Clin Sci (Lond).* 2016 Feb;130(3):193-203. doi: 10.1042/CS20150405. PMID: 26558403
25. Canals I, Soriano J, Orlandi JG, Torrent R, Richaud-Patin Y, Jiménez-Delgado S, Merlin S,

- Follenzi A, Consiglio A, Vilageliu L, Grinberg D, Raya A. Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks.** *Stem Cell Reports*. 2015 Oct 13;5(4):546-57. doi: 10.1016/j.stemcr.2015.08.016. PMID: 26411903
26. Bosetti M, Borrone A, **Follenzi A**, Messaggio F, Tremolada C, Cannas M. **Human lipoaspirate as autologous injectable active scaffold for one-step repair of cartilage defects.** *Cell Transplant*. 2016;25(6):1043-56. doi: 10.3727/096368915X689514. PMID: 26395761
27. Oltolina F, Zamperone A, Colangelo D, Gregoletto L, Reano S, Pietronave S, Merlin S, Talmon M, Novelli E, Diena M, Nicoletti C, Musarò A, Filigheddu N, **Follenzi A**, Prat M. **Human Cardiac Progenitor Spheroids Exhibit Enhanced Engraftment Potential.** *PLoS One*. 2015 Sep 16;10(9):e0137999. doi: 10.1371/journal.pone.0137999. PMID: 26375957 **Correction: PLoS One. 2015 Oct 23;10(10):e0141632. doi: 10.1371/journal.pone.0141632. PMID: 26495969.**
28. Grasso G, Deriu MA, Prat M, Rimondini L, Vernè E, **Follenzi A**, Danani A. **Cell Penetrating Peptide Adsorption on Magnetite and Silica Surfaces: A Computational Investigation.** *J Phys Chem B*. 2015 Jul 2;119(26):8239-46. doi: 10.1021/jp512782e. PMID: 26042722
29. Zanolini D, Merlin S, Feola M, Ranaldo G, Amoruso A, Gaidano G, Zaffaroni M, Ferrero A, Brunelleschi S, Valente G, Gupta S, Prat M, **Follenzi A**. **Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.** *Haematologica*. 2015 Jul;100(7):881-92. doi: 10.3324/haematol.2014.123117.
30. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, **Follenzi A**, Quagliata L, Ledda-Columbano GM, Terracciano L, Giordano S, Columbano A. **Nrf2, but not β -catenin, mutation represents an early event in rat hepatocarcinogenesis.** *Hepatology*. 2015 Sep;62(3):851-62. doi: 10.1002/hep.27790. PMID: 25783764
31. Mandili G, Alchera E, Merlin S, Imarisio C, Chandrashekar BR, Riganti C, Bianchi A, Novelli F, **Follenzi A**, Carini R. **Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation.** *J Hepatol*. 2015 Mar;62(3):573-80. doi: 10.1016/j.jhep.2014.10.007.
32. Babad J, Mukherjee G, **Follenzi A**, Ali R, Roep BO, Shultz LD, Santamaria P, Yang OO, Goldstein H, Greiner DL, Di Lorenzo TP. **Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.** *Clin Exp Immunol*. 2015 Mar;179(3):398-413. doi: 10.1111/cei.12465.
33. Aspesi A, Pavesi E, Robotti E, Crescitelli R, Boria I, Avondo F, Moniz H, Da Costa L, Mohandas N, Roncaglia P, Ramenghi U, Ronchi A, Gustincich S, Merlin S, Marengo E, Ellis SR, **Follenzi A**, Santoro C, Dianzani I. **Dissecting the transcriptional phenotype of ribosomal protein deficiency: implications for Diamond-Blackfan Anemia.** *Gene*. 2014 Jul 25;545(2):282-9. doi: 10.1016/j.gene.2014.04.077.
34. Park HY, Lim H, Yoon YJ, **Follenzi A**, Nwokafor C, Lopez-Jones M, Meng X, Singer RH. **Visualization of dynamics of single endogenous mRNA labeled in live mouse.** *Science*. 2014 Jan 24;343(6169):422-4. doi: 10.1126/science.1239200 PMID: 24458643
35. Pietronave S, Zamperone A, Oltolina F, Colangelo D, **Follenzi A**, Novelli E, Diena M, Pavesi A, Consolo F, Fiore GB, Soncini M, Prat M. **Monophasic and biphasic electrical stimulation induces a precardiac differentiation in progenitor cells isolated from human heart.** *Stem Cells Dev*. 2014 Apr 15;23(8):888-98. doi: 10.1089/scd.2013.0375. PMID: 24328510
36. Zamperone A, Pietronave S, Merlin S, Colangelo D, Ranaldo G, Medico E, Di Scipio F, Berta GN, **Follenzi A**, Prat M. **Isolation and characterization of a spontaneously immortalized multipotent mesenchymal cell line derived from mouse subcutaneous adipose tissue.** *Stem Cells Dev*. 2013 Nov 1;22(21):2873-84. doi: 10.1089/scd.2012.0718. PMID: 23777308

37. Scharf B, Clement CC, Wu XX, Morozova K, Zanolini D, **Follenzi A**, Larocca JN, Levon K, Sutterwala FS, Rand J, Cobelli N, Purdue E, Hajjar KA, Santambrogio L. **Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris.** Nat Commun. 2012 Mar 27;3:755. doi: 10.1038/ncomms1754. PMID: 22453828
38. Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker-Menezes D, **Follenzi A**, Crosariol M, Llaverias G, Sotgia F, Pestell RG, Lisanti MP. **Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice. Role of Cav1 in Shh heterotypic signaling and transendothelial migration.** Cancer Res. 2012 May 1;72(9):2262-74. doi: 10.1158/0008-5472.CAN-11-2593. PMID: 22396494
39. Cotella D, Radicke S, Cipriani V, Cavaletto M, Merlin S, **Follenzi A**, Ravens U, Wettwer E, Santoro C, Sblattero D. **N-glycosylation of the mammalian dipeptidyl aminopeptidase-like protein 10 (DPP10) regulates trafficking and interaction with Kv4 channels.** Int J Biochem Cell Biol. 2012 Jun;44(6):876-85. doi: 10.1016/j.biocel.2012.02.011. PMID: 22387313
40. Noh KM, Hwang JY, **Follenzi A**, Athanasiadou R, Miyawaki T, Grealley JM, Bennett MV, Zukin RS. **Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal death.** Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):E962-71. doi: 10.1073/pnas.1121568109. PMID: 22371606
41. **Follenzi A**, Raut S, Merlin S, Sarkar R and Gupta S. **Role of bone marrow cell transplantation for correcting hemophilia A in mice.** Blood. 2012 Jun 7;119(23):5532-42. doi: 10.1182/blood-2011-07-367680. PMID: 22368271
42. Kumar M, **Follenzi A**, Garforth S, Gupta S. **Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches.** Antivir Ther. 2011 Dec 13. doi: 10.3851/IMP2014
43. Paroder-Belenitsky M, Maestas MJ, Dohán O, Nicola JP, Reyna-Neyra A, **Follenzi A**, Dadachova E, Eskandari S, Amzel LM, Carrasco N. **Mechanism of anion selectivity and stoichiometry of the Na⁺/I⁻ symporter (NIS).** Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17933-8. doi: 10.1073/pnas.1108278108. PMID: 22011571
44. Dal Ponte C, Alchera E, **Follenzi A**, Imarisio C, Prat M, Albano E, Carini R. **Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury.** Liver Transpl. 2011 Apr;17(4):474-82. doi: 10.1002/lt.22256. PMID: 21445931
45. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, **Follenzi A**, Potolicchio I, Nieves E, Cuervo AM, Santambrogio L. **Microautophagy of cytosolic proteins by late endosomes.** Dev Cell. 2011 Jan 18;20(1):131-9. doi: 10.1016/j.devcel.2010.12.003. **Erratum in: Dev Cell. 2011 Mar 15;20(3):405-6.** PMID: 21238931
46. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, **Follenzi A**, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW and Rivella S. (2010) **Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice.** J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. PMID: 21099112
47. Ramos P, Guy E, Chen N, Proenca CC, Gardenghi S, Casu C, **Follenzi A**, Van Rooijen N, Grady RW, de Sousa M, Rivella S. **Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis.** Blood. 2011 Jan 27;117(4):1379-89. doi: 10.1182/blood-2010-09-307462. PMID: 21059897

48. Maitra R, **Follenzi A**, Yaghoobian A, Montagna C, Merlin S, Cannizzo ES, Hardin JA, Cobelli N, Stanley ER, Santambrogio L. **Dendritic cell-mediated in vivo bone resorption**. *J Immunol*. 2010 Aug 1;185(3):1485-91. doi: 10.4049/jimmunol.0903560. PMID: 20581147
49. Cheng K, **Follenzi A**, Surana M, Fleischer N, Gupta S. **Switching of mesodermal and endodermal properties in hTERT-modified and expanded fetal human pancreatic progenitor cells**. *Stem Cell Res Ther*. 2010 Mar 15;1(1):6. doi: 10.1186/scrt6. PMID: 20504287
Erratum in: Stem Cell Res Ther. 2015 Sep 30;6:189. doi: 10.1186/s13287-015-0176-0. PMID: 26424142
50. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, **Follenzi A**, Goldstein H. **Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody**. *J Virol*. 2010 Jul;84(13):6645-53. doi: 10.1128/JVI.02339-09. PMID: 20410262
51. Circosta P, Granziero L, **Follenzi A**, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A. **TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR**. *Hum Gene Ther*. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117. PMID: 19678763
52. Krohn N, Kapoor N, Enami Y, **Follenzi A**, Bandi S, Joseph B and Gupta S **Hepatocyte Transplantation-Induced Liver Inflammation Is Driven by Cytokines-Chemokines Associated With Neutrophils and Kupffer Cells**. *Gastroenterology*. 2009 May;136(5):1806-17. PMID: 19422086
53. Salvucci O, Maric D, Economopoulou M, Merlin S, **Follenzi A**, Tosato G. **Ephrin B reverse signaling contributes to endothelial and mural cell assembly into vascular structures**. *Blood*. 2009 Aug 20;114(8):1707-16. doi: 10.1182/blood-2008-12-192294. PMID: 19411631
54. Miyawaki T, Ofengeim D, Noh KM, Latuszek-Barrantes A, Hemmings BA, **Follenzi A**, Zukin RS. **The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death**. *Nat Neurosci*. 2009 May;12(5):618-26. doi: 10.1038/nn.2299. PMID: 19349976
55. Merlin S, Pietronave S, Locarno D, Valente G, **Follenzi A** and Prat M. **Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene**. *Cancer Sci*. 2009 Apr;100(4):633-8. doi: 10.1111/j.1349-7006.2008.01079.x. PMID: 19175607
56. Kojaoghlanian T, Joseph A, **Follenzi A**, Zheng JH, Leiser M, Fleisher N, Horwitz MS, Di Lorenzo TP, and Goldstein H. **Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice**. *Gene Ther*. 2009 Mar;16(3):340-8. doi: 10.1038/gt.2008.172. PMID: 19112449
57. Inada M, **Follenzi A**, Surana M, Cheng K, Joseph B, Benten D, Bandi S, Qian H and Gupta S. **Phenotype reversion in fetal human liver epithelial cells identifies the role of an intermediate meso-endodermal stage before hepatic maturation**. *J Cell Sci*. 2008 Apr 1;121(Pt 7):1002-13. doi: 10.1242/jcs.019315. PMID: 18319302
58. **Follenzi A**, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. **Transplanted Endothelial Cells Repopulate the Liver Endothelium and Correct the Phenotype of Hemophilia A Mice**. *J Clin Invest*. 2008 Mar;118(3):935-45. doi: 10.1172/JCI32748. PMID: 18274668
59. Massey AC, **Follenzi A**, Kiffin R, Zhang C and Cuervo AM. **Early cellular changes after blockage of chaperone-mediated autophagy**. *Autophagy*. 2008 May;4(4):442-56. PMID:

18253088

60. Joseph A, Zheng JH, **Follenzi A**, Di Lorenzo T, Sango K, Hyman J, Chen K, Piechocka-Trocha A, Brander C, Hooijberg E, Vignali DA, Walker BD and Goldstein H. **Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.** *J Virol.* 2008 Mar;82(6):3078-89. doi: 10.1128/JVI.01812-07. PMID: 18184707
61. Martinez-Vicente M, Tallozy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, **Follenzi A**, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM. **Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.** *J Clin Invest.* 2008 Feb;118(2):777-88. doi: 10.1172/JCI32806. PMID: 18172548
62. Venugopal SK, J Wu, AM Catana, L Eisenbud, SQ He, YY Duan, **Follenzi A** and Zern MA. **Lentivirus-mediated superoxide dismutase1 gene delivery protects against oxidative stress induced liver injury in mice.** *Liver Int.* 2007 Dec;27(10):1311-22. PMID: 18036097
63. Venugopal SK, Chen J, Zhang Y, Clemens D, **Follenzi A**, Zern MA. **Role of MAPK phosphatase-1 in sustained activation of JNK during ethanol-induced apoptosis in hepatocyte-like VL-17A cells.** *J Biol Chem.* 2007 Nov 2;282(44):31900-8. PMID: 17848570
64. Annoni A, Battaglia M, **Follenzi A**, Lombardo A, Sergi-Sergi L, Naldini L, Roncarolo MG. **The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells.** *Blood.* 2007 Sep 15;110(6):1788-96. PMID: 17495135
65. Wang ZV, Schraw TD, Kim JY, Khan T, Rajala MW, **Follenzi A** and Scherer PE. **Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention.** *Mol Cell Biol.* 2007 May;27(10):3716-31. PMID: 17353260
66. Mortellaro A, Hernandez RJ, Guerrini MM, Carlucci F, Tabucchi A, Ponzoni M, Sanvito F, Doglioni C, Di Serio C, Biasco L, **Follenzi A**, Naldini L, Bordignon C, Roncarolo MG, Aiuti A. **Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.** *Blood.* 2006 Nov 1;108(9):2979-88. PMID: 16835374
67. Kumaran V, Benten D, **Follenzi A**, Joseph B, Sarkar R, and Gupta S. **Transplantation of endothelial cells corrects the phenotype in hemophilia A mice.** *J Thromb Haemost.* 2005 Sep;3(9):2022-31. PMID: 16102109
68. Luca T, Givogri MI, Perani L, Galbiati F, **Follenzi A**, Naldini L, Bongarzone ER. **Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery.** *Mol Ther.* 2005 Oct;12(4):669-79. PMID: 16087406
69. Abordo-Adesida E, **Follenzi A**, Barcia C, Sciascia S, Castro M, Naldini L and Lowenstein P. **Stability of Lentiviral Vector-Mediated Transgene Expression in the Brain in the Presence of Systemic anti-Vector Immune Responses.** *Hum Gene Ther.* 2005 Jun;16(6):741-51. PMID: 15960605
70. Benten D, **Follenzi A**, Bhargava KK, Kumaran V, Palestro CJ, Gupta S. **Hepatic Targeting of Transplanted Liver Sinusoidal Endothelial Cells in Intact Mice.** *Hepatology.* 2005 Jul;42(1):140-8. PMID: 15918158
71. Cignetti A, Vallario A, **Follenzi A**, Circosta P, Capaldi A, Gottardi D, Naldini L, Caligaris-Cappio F. **Lentiviral Transduction of Primary Myeloma Cells with CD80 and CD154 Generates Anti-Myeloma Effector T Cells.** *Hum Gene Ther.* 2005 Apr;16(4):445-56. PMID: 15871676

72. Vigna E, Amendola M, Benedicenti F, Simmons AD, **Follenzi A** and Naldini L. **Efficient Tet-Dependent Expression of Human Factor IX in vivo by a new self-regulating lentiviral vector.** Mol Ther. 2005 May;11(5):763-75. PMID: 15851015
73. Boccaccio C, Sabatino G, Medico E, Girolami F, **Follenzi A**, Reato G, Sottile A, Naldini L and Comoglio PM. **The MET oncogene drives a genetic program linking cancer to hemostasis.** Nature. 2005 Mar 17;434(7031):396-400. PMID: 15772665
74. Taulli R, Accornero P, **Follenzi A**, Mangano T, Morotti A, Scuoppo C, Forni PE, Crepaldi T, Chiarle R, Naldini L and Ponzetto C. **RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.** Cancer Gene Ther. 2005 May;12(5):456-63. PMID: 15719029
75. Di Natale P, Di Domenico C, Gargiulo N, Castaldo S, Gonzalez E, Mithbaokar P, De Felice M, **Follenzi A**, Naldini L and Villani G.R.D. **Treatment of the Mouse Model of Mucopolysaharidosis Type IIIB with Lentiviral-NAGLU Vector** Biochem J. 2005 Jun 1;388(Pt 2):639-46. PMID: 15649123
76. Duprè L, Trifari S, **Follenzi A**, Marangoni F, Lain de Lera T, Bernard A, Martino S, Tsuchiya S, Bordignon C, Naldini L, Aiuti A, Roncarolo MG. **Lentiviral Vector-Mediated Gene Transfer in T Cells from Wiskott-Aldrich Syndrome Patients Leads to Functional Correction** Mol Ther. 2004 Nov;10(5):903-15. PMID: 15509508
77. Consiglio A, Gritti A, Dolcetta D, **Follenzi A**, Bordignon C, Gage FH, Vescovi AL, Naldini L. **Robust In Vivo Gene Transfer into Adult Mammalian Neural Stem Cells by Lentiviral Vectors.** Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14835-40. PMID: 15466696
78. **Follenzi A**, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. **Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.** Blood. 2004 May 15;103(10):3700-9. PMID: 14701690
79. Ruggiero T, Olivero M, **Follenzi A**, Naldini L, Calogero R, Di Renzo MF. **Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR.** Nucleic Acids Res. 2003 Nov 15;31(22):6561-9. PMID: 14602915
80. Bonci D, Cittadini A, Latronico MV, Borello U, Aycok JK, Drusco A, Innocenzi A, **Follenzi A**, Lavitrano M, Monti MG, Ross J Jr, Naldini L, Peschle C, Cossu G, Condorelli G. **'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo.** Gene Ther. 2003 Apr;10(8):630-6. PMID: 12692591
81. Janssens W, Chuah MK, Naldini L, **Follenzi A**, Collen D, Saint-Remy JM, VandenDriessche T. **Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent.** Hum Gene Ther. 2003 Feb 10;14(3):263-76. PMID: 12639306
82. Manganini M, Serafini M, Bambacioni F, Casati C, Erba E, **Follenzi A**, Naldini L, Bernasconi S, Gaipa G, Rambaldi A, Biondi A, Golay J, Intronà M. **A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors.** Hum Gene Ther. 2002 Oct 10;13(15):1793-807. PMID: 12396613
83. Vanden Driessche T, Thorrez L, Naldini L, **Follenzi A**, Moons L, Berneman Z, Collen D, and Chuah MK. **Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo.** Blood. 2002 Aug 1;100(3):813-22. PMID: 12130491
84. Villani GR, **Follenzi A**, Vanacore B, Di Domenico C, Naldini L and Di Natale P. **Correction of mucopolysaccharidosis type IIIB fibroblasts by lentiviral vector-mediated gene transfer.** Biochem J. 2002 Jun 15;364(Pt 3):747-53. PMID: 12049639

85. Di Natale P, Di Domenico C, Villani GR, Lombardo A, **Follenzi A**, and Naldini L. **In vitro gene therapy of mucopolysaccharidosis type 1 by lentiviral vectors.** Eur J Biochem. 2002 Jun;269(11):2764-71. PMID: 12047386
86. **Follenzi A**, Sabatino G, Lombardo A, Boccaccio C and Naldini L. **Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors.** Hum Gene Ther. 2002 Jan 20;13(2):243-60. PMID: 11812281
87. Condorelli G, Borello U, De Angelis L, Latronico M, Sirabella D, Coletta M, Galli R, Balconi G, **Follenzi A**, Frati G, Cusella De Angelis MG, Gioglio L, Amuchastegui S, Adorini L, Naldini L, Vescovi A, Dejana E, Cossu G., **Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration.** Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10733-8. PMID: 11535818
88. Stella MC, Vercelli A, Repici M, **Follenzi A** and Comoglio PM. **Macrophage stimulating protein is a novel neurotrophic factor.** Mol Biol Cell. 2001 May;12(5):1341-52. PMID: 11359926
89. **Follenzi A**, Bakovic S, Gual P, Stella MC, Longati P and Comoglio PM. **Cross-talk between the proto-oncogenes Met and Ron.** Oncogene. 2000 Jun 22;19(27):3041-9. PMID: 10871856
90. **Follenzi A**, Ailles LE, Bakovic S, Geuna M and Naldini L. **Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.** Nat Genet. 2000 Jun;25(2):217-22. PMID: 10835641
91. Medico E, Mongioli AM, Huff J, Jelinek MA, **Follenzi A**, Gaudino G, Parsons JT and Comoglio PM. **The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro.** Mol Biol Cell. 1996 Apr;7(4):495-504. PMID: 8730094
92. Gaudino G, Avvantaggiato V, **Follenzi A**, Acampora D, Simeone A and PM Comoglio. **The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues.** Oncogene. 1995 Dec 21;11(12):2627-37. PMID: 8545120
93. Silvagno F*, **Follenzi A***, Arese M, Prat M, Montrucchio G, Gaudino G, Camussi G, Comoglio PM, and Bussolino F. **In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis.** Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1857-65. PMID: 7583565 *co-share 1st author.
94. Naldini L, Vigna E, Bardelli A, **Follenzi A**, Galimi F, and Comoglio PM. **Biological activation of pro- HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.** J Biol Chem. 1995 Jan 13;270(2):603-11. PMID: 7822285
95. Galimi F, Bagnara GP, Bonsi L, Cottone E, **Follenzi A**, Simeone A, and Comoglio PM. **Hepatocyte growth factor induces proliferation and differentiation of multipotent hematopoietic progenitors.** J Cell Biol. 1994 Dec;127(6 Pt 1):1743-54. PMID:7528222
96. Gaudino G, **Follenzi A**, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ and Comoglio, PM. **Ron is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.** EMBO J. 1994 Aug 1;13(15):3524-32. PMID:8062829

REVIEWS E CAPITOLI DI LIBRI

1. Merlin S, Follenzi A. **Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors.** Mol Ther Methods Clin Dev. 2019 Jan 8;12:223-232. doi: 10.1016/j.omtm.2018.12.013. eCollection 2019 Mar 15. PMID: 30775404
2. Aspesi A, Borsotti C, Follenzi A. **Emerging Therapeutic Approaches for Diamond Blackfan Anemia.** Curr Gene Ther. 2018;18(6):327-335. doi: 10.2174/1566523218666181109124538. PMID: 30411682

3. Borsotti C, Follenzi A. **New technologies in gene therapy for inducing immune tolerance in hemophilia A**. *Expert Rev Clin Immunol*. 2018 Dec;14(12):1013-1019. doi: 10.1080/1744666X.2018.1539667. Epub 2018 Nov 3. PMID: 30345839
4. Borsotti C, Borroni E, **Follenzi A. Lentiviral vector interactions with the host cell**. *Curr Opin Virol*. 2016 Dec;21:102-108. doi: 10.1016/j.coviro.2016.08.016. PMID: 27637073
5. Alchera E, Imarisio C, Mandili G, Merlin S, Chandrashekar BR, Novelli F, **Follenzi A**, Carini R. **Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected Liver Cell Phenotype**. *Biomed Res Int*. 2015; 2015:286746. doi: 10.1155/2015/286746. Review. PMID: 26539478
6. Gardenghi S, Ramos P, **Follenzi A**, Rao N, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S. **Hepcidin and Hfe in iron overload in beta-thalassemia**. *Ann N Y Acad Sci*. 2010 Aug;1202:221-5. doi: 10.1111/j.1749-6632.2010.05595.x. PMID: 20712796
7. **Follenzi A**. and Vigna E. **Lentiviral Vectors for Cancer Gene Therapy**. Chapter 5, pages 83-94 In: Kevin Harrington and Hardev Pandha. **Viral Therapy of Cancer**. ISBN: 978 0 470 01922. : John Wiley & Sons Ltd (United Kingdom) (2008).
8. **Follenzi A.**, Santambrogio L., Annoni A. **Immune responses to lentiviral vectors**. *Curr Gene Ther*. 2007 Oct;7(5):306-15. PMID: 17979677
9. **Follenzi A.**, Gupta S. **The promise of lentiviral gene therapy for liver cancer**. *J Hepatol*. 2004 Feb;40(2):337-40. Review. PMID: 14739109
10. **Follenzi A.** and Naldini L. **Generation of HIV-1 derived lentiviral vectors**. *Methods in Enzymology - Gene Therapy Methods*, Ed, M. Ian Phillips, 346:454-465 (2002). PMID: 11883085
11. **Follenzi A.** and Naldini L. **"HIV-based vectors: Preparation and use"**. *Methods Mol Med* 69:259-74 (2002). PMID: 11987783
12. **Follenzi A** and Naldini L. **Lentiviral vectors for gene therapy**. In: BERTOLOTTI R., PARVEZ S.H., AND NAGATSU T. *Progress in Gene Therapy: Basic and Clinical Frontiers*. ISBN: 90-6764-328-9. LEIDEN: VSP (NETHERLANDS) (2000).
13. Gaudino G., Follenzi A., and Comoglio PM. **Hepatocyte growth factor/scatter factor: a mitogen and a motility factor**. *Acta Medica Romana* 29:370-378 (1991).

RELATRICE INVITATA A CONFERENZE INTERNAZIONALI

- Follenzi A, 2019 HEMO, Brazilian Association of Hematology, Hemotherapy and cellular therapy congress, 6-9 November 2019, Rio de Janeiro, Brazil)
- Follenzi A, microRNA-regulated lentiviral gene therapy for treatment and immune tolerance in hemophilia. **America Association of Immunology Conference, ASGCT Symposia: Immunologic Responses to Gene Therapy for Hemophilia** (4-8 May 2018, Austin, TX, USA)
- Follenzi A,.....**Adavanced Therapies in Health Care Symposium**, Sidra Medical and Research Center, Doha, Qatar (28-29 October 2017)

- Follenzi A,Challenges for Cell and Gene Therapy for Hemophilia A. 2nd Functional Genomics: Nature Via Nurture Symposium, Sidra Medical and Research Center, Doha, Qatar (12-14 December 2016).
- Follenzi A, Targeting FVIII-expression to Liver Sinusoidal Cells to correct the bleeding phenotype in Hemophilia A. FTNLS symposium on 'Gene Therapy: from state-of-the-art technologies to clinical translation' (4-5 June 2015, Brussels, Belgio).
- Merlin S, Cannizzo ES, and Follenzi A. Targeting FVIII-Expression To Liver Sinusoidal Cells By Lentiviral Vectors Corrects the Bleeding Phenotype in Hemophilia A Overcoming Immunological Responses. The 18th Annual Meeting of the American Society of Gene Therapy, New Orleans, LA (Maggio 13-16, 2015).
- Follenzi A, FVIII gene transfer to liver sinusoidal cells to correct the bleeding phenotype in hemophilia A. 12th Workshop on Novel Technologies and Gene Transfer for Hemophilia, Washington, DC (Ottobre 24-25, 2014).
- Follenzi A, Targeting FVIII Expression to Myeloid Cells to Overcome Immunological Responses to Gene Therapy for Hemophilia A. The 17th Annual Meeting of the American Society of Gene Therapy, Washington, DC (Maggio 21-24, 2014).
- Follenzi A, "Transcriptional and post-transcriptional targeting of FVIII expression to overcome immunological responses to gene therapy for Hemophilia A" XXI ESGCT Annual Meeting, Madrid, Spagna (25-28 Ottobre 2013).
- Follenzi A, Transcriptional and post-transcriptional regulation to overcome immunological responses to gene therapy for Hemophilia A. The 16th Annual Meeting of the American Society of Gene Therapy, Salt Lake City, UT (Maggio 15-18, 2013).
- Follenzi A, Merlin S and Gupta S. Long-Term Survival Of Primary Kupffer Cells After Transplantation Into Syngeneic Mouse Recipients. XVIII ESGCT Annual Meeting, Milano, Italia (22- 25 Ottobre 2010).
- Follenzi A. Bone Marrow Transplantation Corrects the Bleeding Phenotype of Hemophilia A Mice. Tenth Workshop on Novel Technologies and Gene Transfer for Hemophilia. Chapel Hill, NC (5-6 Febbraio 2010).
- Follenzi A. Cell therapy with genetically-modified liver sinusoidal endothelial cells corrects bleeding phenotype of hemophilia A mice. 59th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA (Ottobre 30 - Novembre 2, 2009). Plenary Session.
- Follenzi A. Transplanted Endothelial Cells Repopulate the Liver Endothelium and Correct the Phenotype of Hemophilia A Mice, XVI ESGCT Annual Meeting, Bruges, Belgio (13-16 Novembre 2008).
- Follenzi A, Sarka R, Raut S and Gupta S. Bone Marrow Transplantation Corrects the Bleeding Phenotype of Hemophilia A Mice Through Reconstitution of FVIII Expression in Nonparenchymal Cells. 58th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA (Novembre 1-4 2008).
- Follenzi A, Transplanted Endothelial Cells Repopulate the Liver Endothelium and Correct the Phenotype of Hemophilia A Mice. Ninth Workshop on Novel Technologies and Gene Transfer for Hemophilia sponsored by the National Hemophilia Foundation (22-23 Febbraio 2008, The Children's Hospital of Philadelphia - PA).
- Follenzi A, Ulla M, Novikoff P and Gupta S. Reconstitution of the mouse liver with genetically modified liver sinusoidal endothelial cells (LSEC) for biological studies and cell and gene therapy applications. 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA (Ottobre 27-31 2006).

- Follenzi A, Benten D, Ulla M, De Palma M, Novikoff P and Gupta S. Genetic manipulation of liver sinusoidal endothelial cells (LSEC) and repopulation of the mouse liver with transplanted LSEC has therapeutic implications. The 9th Annual Meeting of the American Society of Gene Therapy, Baltimore, MD (Maggio 31- Giugno 4, 2006).
- Follenzi A, Benten D, Novikoff P and Gupta S. Reconstitution of the mouse liver with transplanted liver sinusoidal endothelial cells (LSEC) has implications for cell and gene therapy. 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA (Novembre 11–15, 2005).
- Follenzi A, Benten D, Kumaran V, Sarkar R and Gupta S. The use of Liver Sinusoidal Endothelial Cells (LSEC) for Liver-Directed Cell Therapy. 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA (Ottobre 30-Novembre 2, 2004).
- Follenzi A, Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors limits transgene-specific immune response. Lentivectors WORKSHOP, ISREC, LAUSANNE, CH (16 Maggio, 2002).
- Follenzi A, Development and use of lentiviral vectors, ESF/EMRC EXPLORATORY WORKSHOP ON: Chronic inflammation: basic mechanisms and therapeutic targets London, UK (19-21 Settembre 2001).
- Follenzi A. Lentiviral vectors a new tool for Gene Transfer and Therapy- 10th European Congress on Biotechnology, Madrid, Spagna (8 - 11 Luglio, 2001).
- Follenzi A, Ailles LE, Bakovic S, Geuna M and Naldini L. Gene transduction by lentiviral vectors is limited by nuclear translocation of the genome and is rescued by incorporation of cis- acting sequences from the HIV-1 pol gene. The 3th annual meeting of the American Society of Gene Therapy, Denver, CO (Maggio 31-Giugno 4, 2000).

Inoltre, numerosi Poster presentati a conferenze internazionali durante gli anni passati.